About this trial

Hereditary thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) is a rare disorder characterized by thrombocytopenia as a result of platelet consumption, microangiopathic hemolytic anemia, occlusion of the microvasculature with von Willebrand factor-platelet-thrombic and ischemic end organ damage. The underlying patho-mechanism is a severe congenital ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, 13) deficiency which is the result of compound heterozygous or homozygous ADAMTS13 gene mutations.

Although considered a monogenic disorder the clinical presentation in Upshaw-Schulman syndrome patients varies considerably without an apparent genotype-phenotype correlation. In 2006 we have initiated a registry for patients with Upshaw-Schulman syndrome and their family members to identify possible triggers of acute bouts of TTP, to document individual clinical courses and treatment requirements as well as possible side effects of long standing plasma substitution, e.g. alloantibody formation or viral infections.

Eligibility criteria

Qualifiers

Severe ADAMTS13 deficiency ( ≤ 10% activity) and no ADAMTS 13 inhibitor on two or more occasions at least one month apart

Being a family member of a confirmed or suspected patient

Molecular analysis of ADAMTS13 gene with one or more mutations and/or positive infusion trial (full recovered ADAMTS13 activity after infused fresh frozen plasma (FFP) with a plasma half-life of 2-4 days)

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Observation

Treatment groups

450 Participants
are divided into 2 treatment groups

Locations

7
Austria
Medical University of Vienna, Department of Medicine 1, Div. Hematology and Hemostasis Waehringer Guertel 18-20A-1090, Vienna Austria
Czechia
Institute of Hematology and Blood Transfusion, Coagulation Laboratory, U nemocnice 1CZ-12820, Prague Czechia
Germany
University Medical Center Hamburg-Eppendorf, Department of Pediatric Hematology and Oncology, Martinistr 52D-20246, Hamburg Germany
Japan
Nara Medical University, Department of Blood Transfusion Medicine, Shijyo-cho 840634-8522, KashiharaNara, Japan

Sponsors and collaborators

Insel Gruppe AG, University Hospital Bern

Lead sponsor

Swiss National Science Foundation

Collaborator

Mach Gaensslen Foundation

Collaborator

Baxalta Innovations GmbH, Wien, Austria

Collaborator